Jiangxi Fushine Pharmaceutical Co Ltd (300497) — Tangible Net Worth Ratio
Jiangxi Fushine Pharmaceutical Co Ltd (300497) has a Tangible Net Worth Ratio of 87.4% as of March 2026. This metric is calculated by deducting intangible assets (CN¥285.64 Million) from net assets (CN¥2.27 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore Jiangxi Fushine Pharmaceutical Co Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Jiangxi Fushine Pharmaceutical Co Ltd Tangible Net Worth Ratio (2011–2025)
This chart shows how Jiangxi Fushine Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 87.4%, reflecting net assets of CN¥2.27 Billion with intangible assets of CN¥285.64 Million CNY. For live market cap and overall valuation, see Jiangxi Fushine Pharmaceutical Co Ltd (300497) market capitalisation.
Annual Tangible Net Worth Ratio for Jiangxi Fushine Pharmaceutical Co Ltd (2011–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Jiangxi Fushine Pharmaceutical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore 300497 capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 86.9% | CN¥2.20 Billion | CN¥287.85 Million | CN¥4.40 Billion | ▼ -2.3 pp |
| 2024 | 89.2% | CN¥2.18 Billion | CN¥235.00 Million | CN¥4.54 Billion | ▼ -1.0 pp |
| 2023 | 90.2% | CN¥2.47 Billion | CN¥241.07 Million | CN¥4.82 Billion | ▼ -0.5 pp |
| 2022 | 90.7% | CN¥2.69 Billion | CN¥249.71 Million | CN¥5.06 Billion | ▼ -0.5 pp |
| 2021 | 91.2% | CN¥2.91 Billion | CN¥256.32 Million | CN¥4.68 Billion | ▼ -0.7 pp |
| 2020 | 91.9% | CN¥3.05 Billion | CN¥246.28 Million | CN¥4.05 Billion | ▼ -0.5 pp |
| 2019 | 92.4% | CN¥1.53 Billion | CN¥116.51 Million | CN¥2.60 Billion | ▲ +1.3 pp |
| 2018 | 91.1% | CN¥1.15 Billion | CN¥102.58 Million | CN¥2.20 Billion | ▲ +2.2 pp |
| 2017 | 88.9% | CN¥966.71 Million | CN¥107.75 Million | CN¥1.79 Billion | ▼ -0.5 pp |
| 2016 | 89.3% | CN¥784.17 Million | CN¥83.80 Million | CN¥1.40 Billion | ▼ -0.5 pp |
| 2015 | 89.8% | CN¥596.21 Million | CN¥60.85 Million | CN¥1.01 Billion | ▲ +11.6 pp |
| 2014 | 78.2% | CN¥283.26 Million | CN¥61.87 Million | CN¥632.35 Million | ▲ +5.7 pp |
| 2013 | 72.5% | CN¥229.76 Million | CN¥63.27 Million | CN¥541.31 Million | ▲ +7.5 pp |
| 2012 | 65.0% | CN¥184.60 Million | CN¥64.62 Million | CN¥476.31 Million | ▲ +16.2 pp |
| 2011 | 48.8% | CN¥120.52 Million | CN¥61.67 Million | CN¥352.57 Million | — |